Clinical Trial Update: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) [Phase 1]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 1 study evaluating loncastuximab tesirine in combination with other anticancer agents for relapsed or refr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING